Clinical Research Directory
Browse clinical research sites, groups, and studies.
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
Sponsor: Amgen
Summary
The primary objective of this trial is to evaluate the effect of olpasiran, compared to placebo, on non-calcified plaque (NCP) volume as measured by Coronary Computed Tomography Angiography (CCTA).
Official title: A Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Safety, Tolerability, and Effect of Olpasiran on Coronary Artery Plaque Burden Assessed by Coronary Computed Tomography Angiography in Participants With Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
Key Details
Gender
All
Age Range
35 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
406
Start Date
2026-03-21
Completion Date
2028-06-02
Last Updated
2025-12-19
Healthy Volunteers
No
Conditions
Interventions
Olpasiran
Olpasiran will be administered SC.
Placebo
Placebo will be administered SC.